Keyphrases
Vitiligo
91%
Alopecia Areata
66%
Pulse Dose
40%
Flap
37%
Corticosteroid Therapy
33%
Melanoma
33%
Hidradenitis Suppurativa
33%
Nivolumab
33%
Pediatric
33%
Lichen Sclerosus
33%
Scalp Wound
33%
Pulley
33%
Lip Reconstruction
33%
Mohs Micrographic Surgery
33%
High-risk Human Papillomavirus (HR-HPV)
33%
Rare Presentation
33%
Vitiligo Treatment
33%
Aplasia
33%
Ointment
33%
Minority Patients
33%
Gender Minority
33%
Successful Treatment
33%
Clinical Recommendations
33%
Teenagers
33%
Dermatologist
33%
Skin Cancer
33%
Bullous
33%
Crisaborole
33%
Dermatologic Surgery
33%
Sexual Minority
33%
Ablative
33%
Health Disparities
33%
Transmission Risk
33%
Bullous Pemphigoid
33%
Linagliptin
33%
Primary Repair
33%
Breast
33%
Microphthalmia
27%
Sclerocornea
27%
Melanocytes
21%
Autoimmune
21%
Scalp
20%
Prednisolone
17%
Local Flap Reconstruction
16%
Cutaneous Flap
16%
Phosphodiesterase 4 Inhibitor
16%
Recurrence Rate
16%
Lip Defect
16%
Myocutaneous Flap
16%
Healthy Tissue
16%
Medicine and Dentistry
Vitiligo
100%
Dermatological Agent
72%
Scalp
60%
Dermatology
40%
Microphthalmia
33%
Cohort Effect
33%
Wound
33%
Crisaborole
33%
Clinical Intervention
33%
Aplasia Cutis Congenita
33%
Human Immunodeficiency Virus
33%
Hidradenitis Suppurativa
33%
Wart Virus
33%
Linagliptin
33%
Nivolumab
33%
Neonatal Infant
33%
Gender Identity
33%
Awareness
33%
Clinical Population
33%
Cheiloplasty
33%
Lichen Sclerosus
33%
Mohs Surgery
33%
Lip
33%
Alopecia Areata
33%
Bullous Pemphigoid
33%
Suture
33%
Melanoma
33%
Disease
28%
Skin Cancer
22%
Melanocyte
20%
Drug Therapy
13%
Phosphodiesterase IV Inhibitor
13%
Eyelash
13%
Gamma Interferon
13%
Skin Defect
11%
Maturity Onset Diabetes of the Young
11%
Recurrence Risk
11%
Dipeptidyl Peptidase-4 Inhibitor
11%
Myocutaneous Flap
11%
Skin Flap
11%
Non Melanoma Skin Cancer
11%
Sun Exposure
11%
Skin Graft
11%
Bleeding
9%
Smoke
8%
Ablation Therapy
8%
Laser Surgery
8%
Virus Particle
8%
Health Hazard
8%
Dermatitis
8%
